BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/12/2014 8:40:00 PM | Browse: 949 | Download: 732
Publication Name World Journal of Gastroenterology
Manuscript ID 3937
Country Portugal
Received
2013-06-03 08:55
Peer-Review Started
2013-06-03 19:30
To Make the First Decision
2013-06-24 10:32
Return for Revision
2013-07-17 12:10
Revised
2013-07-25 07:11
Second Decision
2013-08-13 11:52
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2013-08-13 13:52
Articles in Press
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2013-09-15 14:10
Publish the Manuscript Online
2013-10-18 17:02
ISSN 1007-9327 (print) and 2219-2840 (online)
Open Access
Copyright
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Gastroenterology & Hepatology
Manuscript Type Minireviews
Article Title HER2 therapies and gastric cancer: A step forward
Manuscript Source Invited Manuscript
All Author List Ramon Andrade de Mello, Andrea Marin Marques and António Araújo
Funding Agency and Grant Number
Funding Agency Grant Number
Grants from Janssen and Merck Serono to de Mello RA
Corresponding Author Ramon Andrade de Mello, MD, PhD, Department of Medical Oncology, Gastrointestinal Unit, Portuguese Oncology Institute, Rua Dr. António Bernardino de Almeida, 4200-072 Porto, Portugal. ramondemello@gmail.com
Key Words Gastric cancer; Trastuzumab; c-Met; Human epidermal growth factor receptor 2; Lapatinib; Pertuzumab
Core Tip Approaches for treatment advanced gastric cancer are object of interesting debates toward scientific community worldwide over the last 20 years. Chemotherapy based on platinum and fluoropirimidine agents remained up to now the standard of care for those patients, otherwise triplet therapy either an anthracycline or taxane may be considered. Herein we provide an additional discussion regarding the role of biologic agents, such as trastuzumab and novel therapies for improve survival in this field.
Publish Date 2013-10-18 17:02
Citation de Mello RA, Marques AM, Araújo A. HER2 therapies and gastric cancer: A step forward. World J Gastroenterol 2013; 19(37): 6165-6169
URL http://www.wjgnet.com/1007-9327/full/v19/i37/6165.htm
DOI http://dx.doi.org/10.3748/wjg.v19.i37.6165
Full Article (PDF) WJG-19-6165.pdf
Manuscript File 3937-Review.doc
Answering Reviewers 3937-Answering reviewers.pdf
Copyright License Agreement 3937-Copyright assignment.pdf
Non-Native Speakers of English Editing Certificate 3937-Language certificate.pdf
Peer-review Report 3937-Peer reviewer(s).pdf
Scientific Editor Work List 3937-Scientific editor work list.doc